Compare PEW & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEW | CRBU |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 48.5M |
| IPO Year | 2025 | 2021 |
| Metric | PEW | CRBU |
|---|---|---|
| Price | $1.61 | $0.37 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 405.6K | ★ 2.3M |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $96,449,000.00 | N/A |
| Revenue This Year | $6.38 | $170.62 |
| Revenue Next Year | $6.53 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.57 | N/A |
| 52 Week Low | $1.76 | $0.36 |
| 52 Week High | $3.97 | $2.49 |
| Indicator | PEW | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 25.68 | 24.52 |
| Support Level | N/A | N/A |
| Resistance Level | $2.20 | $0.58 |
| Average True Range (ATR) | 0.12 | 0.04 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 0.70 | 1.08 |
GrabAGun Digital Holdings Inc is a multi-brand eCommerce retailer of firearms, ammunition and related accessories. The Company's firearm products are ordered and paid for by customers online through the Company's eCommerce site and mobile app and are delivered to them on-premises through their choice of federal firearm licensed dealers nationwide. The Company's network of localized firearm dealers perform background checks on firearms purchasers and complete sales forms as mandated by federal and state firearm regulations.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.